Immune-Mediated Colitis due to Concurrent Ipilimumab and Nivolumab Therapy Treated With Infliximab.

Authors :: Karanfilian B
Dalal I
Bhurwal A
Patel AV
Source :: American journal of therapeutics [Am J Ther] 2020 Jul/Aug; Vol. 27 (4), pp. e415-e417.
Publication Year :: 2020

Subjects :: Aged
Antineoplastic Combined Chemotherapy Protocols
Humans
Ipilimumab therapeutic use
Male
Melanoma drug therapy
Nivolumab therapeutic use
Colitis chemically induced
Colitis drug therapy
Infliximab therapeutic use
Ipilimumab adverse effects
Nivolumab adverse effects

Full Text Access

Tools